食物过敏性疾病多发难治，严重影响患者的生活质量，严重时可危及生命。然而，至今临床上尚无真正意义上的抗食物过敏药物，因此抗食物过敏药物的研发迫在眉睫。中国海洋微生物菌种保藏管理中心是国际上最大的海洋微生物库，目前库藏菌株2万多株。前期我们对其中315株深海微生物的2923个粗提物进行了抗食物过敏活性筛选，发现3株深海微生物具有很强的活性，在10μg/mL的浓度下，抑制率分别达到了100、90、76%（相同浓度下，阳性对照药氯雷他定的抑制率为41%）。且产量大、代谢产物丰富。因此，本项目拟以该3株深海微生物为研究对象，以活性为导向，从中寻找发现抗食物过敏活性次级代谢产物，对强活性的目标化合物进行优化发酵和大量富集，深入研究其作用机制，以期发现抗食物过敏先导化合物。通过本项目的研究，最终有望获得具有我国完全自主知识产权的海洋微生物创新药物。

Food allergy is a potentially life-threatening condition with increasing incidence in the last few decades. However, there are no approved treatments currently. Therefore, it is urgent to search for anti-food allergic lead compounds. As the largest preservation center of the marine microbes, the Marine Culture Collection of China (MCCC) owns over 20,000 strains at the present. Previously, we conducted anti-food allergic tests on 2923 crude extracts produced by 315 deep-sea-derived microorganisms of MCCC. As a result, three strains showed potent effect under the concentration of 10 μg/mL with inhibition rates of 100, 90, and 76 %, respectively, compared to 41% of the positive control, loratadine, in the same concentration. Moreover, they were characteristics of large output and rich secondary metabolites. Therefore, they were selected in this project to search for anti-food allergic secondary metabolites using bio-guided isolation. The most potent bioactive compounds will be accumulated by large-scale fermentation under optimized conditions. Then it will be subjected to further bioactive mechanism studies. In general, the project will provide the anti-food allergic lead compounds from marine microorganisms with the self-property right completely owned by our country.